EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome



A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome



Sleep Medicine 8(7-8): 742-752



To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks. A 52-week, multicentre, open-label continuation study involving 310 patients, conducted in 11 countries. Eligible patients from four parent studies were invited to participate. At parent study entry, all patients had a score of > or =15 on the International Restless Legs Scale (IRLS). In this continuation study, all participants received ropinirole, 0.25-4.0 mg once daily, for 52 weeks. The primary study objective was to evaluate the safety of ropinirole. Efficacy was assessed by change in IRLS score, as well as by global improvements (clinical global impression [CGI] scale) and improvements in measures of sleep, work productivity, and quality of life. Overall, 251 (81.0%) patients completed the study. The mean ropinirole dose at study end was 1.90 mg/day. A total of 282 patients (91.3%) reported > or = 1 adverse event. For the majority of patients, the reported adverse events were mild or moderate in intensity. The most common adverse event was nausea. Adverse events led to discontinuation in 8.7% of patients. At week 52, IRLS scores improved by an average of 12.0 points from baseline, and 82.8% of patients were 'much improved' or 'very much improved' on the CGI-improvement scale. Ropinirole treatment was also associated with improvements in measures of sleep and quality of life. Ropinirole was well tolerated and therapeutic efficacy was maintained over 52 weeks in patients with RLS.

(PDF emailed within 0-6 h: $19.90)

Accession: 051057347

Download citation: RISBibTeXText

PMID: 17512789

DOI: 10.1016/j.sleep.2006.09.009



Related references

Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension. Clinical Therapeutics 35(9): 1321-1336, 2014

Ropinirole in Patients With Restless Legs Syndrome and Baseline IRLS Total Scores a 24 Efficacy and Tolerability in a 26-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by a 40-Week Open-Label Extension. 2013

Ropinirole in Patients With Restless Legs Syndrome and Baseline IRLS Total Scores a 24 Efficacy and Tolerability in a 26-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by a 40-Week Open-Label Extension. 2013

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Medicine 9(5): 537-541, 2008

Long-term open-label study of pramipexole in patients with primary restless legs syndrome. Journal of the Neurological Sciences 294(1-2): 62-66, 2010

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet. Neurology 10(8): 710-720, 2011

Ropinirole for restless legs syndrome An Open-Label and Double-Blind Placebo-Controlled Study. Neurology 56(8 Supplement 3): A5, April 24, 2001

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27(4): 674-682, 2004

Ropinirole vs placebo in restless legs syndrome Efficacy, safety and quality of life results from a 12-week double-blind international Study. European Journal of Neurology 10(Supplement 1): 139, September, 2003

The effect of ropinirole on the quality of life in patients with restless legs syndrome in Korea: an 8-week, multicenter, prospective study. Journal of Clinical Neurology 9(1): 51-56, 2013

Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Sleep Medicine 16(11): 1342-1347, 2016

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Movement Disorders 21(10): 1627-1635, 2006

Ropinirole is effective in the treatment of restless legs syndrome A double-blind placebo-controlled 12-week study conducted in 10 countries. Neurology 60(5 Supplement 1): A11-A12, March 11, 2003

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. Journal of Neurology, Neurosurgery, and Psychiatry 75(1): 92-97, 2004

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. Clinical Drug Investigation 36(8): 673-682, 2016